Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Total Current Liabilities: 2020-2025

Historic Total Current Liabilities for Journey Medical (DERM) over the last 4 years, with Sep 2025 value amounting to $39.7 million.

  • Journey Medical's Total Current Liabilities rose 19.15% to $39.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.7 million, marking a year-over-year increase of 19.15%. This contributed to the annual value of $35.2 million for FY2024, which is 15.99% down from last year.
  • According to the latest figures from Q3 2025, Journey Medical's Total Current Liabilities is $39.7 million, which was down 1.89% from $40.5 million recorded in Q2 2025.
  • Over the past 5 years, Journey Medical's Total Current Liabilities peaked at $76.9 million during Q1 2023, and registered a low of $33.3 million during Q3 2024.
  • For the 3-year period, Journey Medical's Total Current Liabilities averaged around $45.2 million, with its median value being $40.2 million (2025).
  • As far as peak fluctuations go, Journey Medical's Total Current Liabilities skyrocketed by 83.93% in 2021, and later tumbled by 49.93% in 2024.
  • Quarterly analysis of 5 years shows Journey Medical's Total Current Liabilities stood at $51.6 million in 2021, then rose by 29.48% to $66.8 million in 2022, then slumped by 37.35% to $41.9 million in 2023, then dropped by 15.99% to $35.2 million in 2024, then rose by 19.15% to $39.7 million in 2025.
  • Its last three reported values are $39.7 million in Q3 2025, $40.5 million for Q2 2025, and $40.2 million during Q1 2025.